K Hidayat1, X Du2, B-M Shi3. 1. Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215006, China. khemzie_khem@yahoo.com. 2. Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215006, China. 3. Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215006, China. shibimin@163.com.
Abstract
We conducted a meta-analysis of observational study to clarify the association between sex hormone-binding globulin (SHBG) levels and the risk of fracture in older adults. We found that higher SHBG levels were associated with an increased risk of fracture in older adults. INTRODUCTION: The association between SHBG levels and the risk of fracture in older adults remains elusive. We aim to clarify this association by conducting a meta-analysis of observational studies. METHODS: PubMed and Web of Science databases were searched for relevant observational studies investigating the association between SHBG levels and the risk of fracture in older adults. The relative risks (RRs) with 95% confidence intervals (CIs) from each study were transformed into a continuous variable for each 1 μg/dL increase in SHBG and were pooled under a random-effects model. RESULTS: A total of 16 observational studies were included in the present meta-analysis. The summary RR of fracture risk associated with each 1 μg/dL increase in SHBG was 1.18 (95% CI 1.11, 1.26); no statistically significant heterogeneity was observed across studies (I2 = 0%, P = 0.67). The positive association was also evident in men (RR 1.22, 95% CI 1.12, 1.33) and women (RR 1.15, 95% CI, 1.05, 1.26). By site of fracture, higher SHBG levels were positively associated with higher risks of hip fracture (RR 1.43, 95% CI 1.23, 1.65), vertebral fracture (RR 1.31, 95% CI 1.12, 1.54), and non-vertebral fracture (RR 1.21, 95% CI 1.06, 1.38). CONCLUSIONS: The present meta-analysis suggests that higher SHBG levels predict an increased risk of fracture in older adults. Further studies should aim to elucidate the complex biological mechanisms by which SHBG may affect fracture risk.
We conducted a meta-analysis of observational study to clarify the association between sex hormone-binding globulin (SHBG) levels and the risk of fracture in older adults. We found that higher SHBG levels were associated with an increased risk of fracture in older adults. INTRODUCTION: The association between SHBG levels and the risk of fracture in older adults remains elusive. We aim to clarify this association by conducting a meta-analysis of observational studies. METHODS: PubMed and Web of Science databases were searched for relevant observational studies investigating the association between SHBG levels and the risk of fracture in older adults. The relative risks (RRs) with 95% confidence intervals (CIs) from each study were transformed into a continuous variable for each 1 μg/dL increase in SHBG and were pooled under a random-effects model. RESULTS: A total of 16 observational studies were included in the present meta-analysis. The summary RR of fracture risk associated with each 1 μg/dL increase in SHBG was 1.18 (95% CI 1.11, 1.26); no statistically significant heterogeneity was observed across studies (I2 = 0%, P = 0.67). The positive association was also evident in men (RR 1.22, 95% CI 1.12, 1.33) and women (RR 1.15, 95% CI, 1.05, 1.26). By site of fracture, higher SHBG levels were positively associated with higher risks of hip fracture (RR 1.43, 95% CI 1.23, 1.65), vertebral fracture (RR 1.31, 95% CI 1.12, 1.54), and non-vertebral fracture (RR 1.21, 95% CI 1.06, 1.38). CONCLUSIONS: The present meta-analysis suggests that higher SHBG levels predict an increased risk of fracture in older adults. Further studies should aim to elucidate the complex biological mechanisms by which SHBG may affect fracture risk.
Entities:
Keywords:
Fracture; Sex hormone-binding globulin; Sex hormones; Sex steroids
Authors: E Legrand; C Hedde; Y Gallois; I Degasne; F Boux de Casson; E Mathieu; M F Baslé; D Chappard; M Audran Journal: Bone Date: 2001-07 Impact factor: 4.398
Authors: J Pfeilschifter; C Scheidt-Nave; G Leidig-Bruckner; H W Woitge; W F Blum; C Wüster; D Haack; R Ziegler Journal: J Clin Endocrinol Metab Date: 1996-07 Impact factor: 5.958
Authors: Claes Ohlsson; Dan Mellström; Daniel Carlzon; Eric Orwoll; Osten Ljunggren; Magnus K Karlsson; Liesbeth Vandenput Journal: J Bone Miner Res Date: 2011-04 Impact factor: 6.741
Authors: R P Stolk; P L Van Daele; H A Pols; H Burger; A Hofman; J C Birkenhäger; S W Lamberts; D E Grobbee Journal: Bone Date: 1996-06 Impact factor: 4.398
Authors: Helena Johansson; John A Kanis; Anders Odén; Eugene McCloskey; Roland D Chapurlat; Claus Christiansen; Steve R Cummings; Adolfo Diez-Perez; John A Eisman; Saeko Fujiwara; Claus-C Glüer; David Goltzman; Didier Hans; Kay-Tee Khaw; Marc-Antoine Krieg; Heikki Kröger; Andrea Z LaCroix; Edith Lau; William D Leslie; Dan Mellström; L Joseph Melton; Terence W O'Neill; Julie A Pasco; Jerilynn C Prior; David M Reid; Fernando Rivadeneira; Tjerd van Staa; Noriko Yoshimura; M Carola Zillikens Journal: J Bone Miner Res Date: 2014-01 Impact factor: 6.741
Authors: L Antonio; D Vanderschueren; N Narinx; K David; J Walravens; P Vermeersch; F Claessens; T Fiers; B Lapauw Journal: Cell Mol Life Sci Date: 2022-10-07 Impact factor: 9.207
Authors: Jenny Pena Dias; Sabina A Haberlen; Adrian S Dobs; Jordan E Lake; Frank J Palella; Lawrence A Kingsley; Jennifer C Price; Shehzad Basaria; Ravi Varadhan; Joseph B Margolick; Chloe L Thio; Todd T Brown Journal: J Acquir Immune Defic Syndr Date: 2021-08-15 Impact factor: 3.771
Authors: Ryan Janjuha; Diane Bunn; Richard Hayhoe; Lee Hooper; Asmaa Abdelhamid; Shaan Mahmood; Joseph Hayden-Case; Will Appleyard; Sophie Morris; Ailsa Welch Journal: Nutrients Date: 2020-05-18 Impact factor: 5.717
Authors: L C Pezzaioli; T Porcelli; A Delbarba; F Maffezzoni; E Focà; F Castelli; C Cappelli; A Ferlin; M E Quiros-Roldan Journal: J Endocrinol Invest Date: 2021-08-30 Impact factor: 4.256